Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2015

View Archived Issues

AMG-334 reduces migraine days in phase II trial

Beth Israel Deaconess Medical Center reports compositions for cardiac regeneration

Anti-EFNA4 antibody-drug conjugate PF-06647263 well tolerated in cancer patients

Compugen selects new B7/CD28-like target for further development

Biodistribution of radiolabeled anti-CD45 monoclonal antibody assessed in patients

[18F]P-238 -- a promising candidate for PSMA PET imaging

Z-04026 and Z-04059: new tracers for myocardial perfusion imaging

Beijing Foreland Pharma patents dual PI3K and mTOR inhibitors

Angion Biomedica to begin phase II trial of BB3 in acute kidney injury

Novartis reports BET inhibitors

Pharmascience discloses BTK inhibitors

Actelion Pharmaceuticals develops TPH1 inhibitors

Bayer Schering Pharma synthesizes MNK1 inhibitors

Results from three trials of anemia candidate JTZ-951 presented

Leidos contracted to support USAID's Malaria Vaccine Development Program

CytoDyn starts first phase III trial of PRO-140 in HIV infection

FDA approves IND for phase IIa trial of Stemedica's MSC therapy in Alzheimer's disease

QLT to transform company through multiple transactions

Caladrius Biosciences, new name for NeoStem

Luminex starts clinical development of Group B Streptococcus assay

Roche to develop companion diagnostic for dalcetrapib

Panasonic Healthcare to take over Bayer diabetes management business

FDA advisory committee recommends approval of Praluent in hypercholesterolemia

Prothena's anti-inflammatory antibody PRX-003 enters phase I

Pozen to acquire Tribute Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...